Comparison Of Efficacy Of Combination Of TAM Formula Vs Kligman Formula For Melasma.

Jinnah Postgraduate Medical Centre

Status and phase

Active, not recruiting

Phase 2

Conditions

Melasma

Treatments

Combination Product: TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)

Combination Product: Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)

Study type

Interventional

Funder types

Other

Identifiers

NCT06013540

NO.F2-81/2022-GENL/255/JPMC

Details and patient eligibility

About

This study would offer the participants about the knowledge of these formula in the treatment of melasma and help the investigators in incorporating and updating the management protocols in medical practice.

Enrollment

122 patients

Sex

All

Ages

25 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

Patients between 25-65 years of age, either gender having melasma for over one month will be included in the study
Exclusion Criteria:
- Pregnancy, breastfeeding, taking birth control pills or plans to become pregnant during the study
- History of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis
- History of skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy
- History of uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy)
- History of sensitivity to hydroquinone or Retin-A
- History of evidence of a compromised immune system or hepatitis